Affiliation: World Health Organization
- Canine leishmaniasisJorge Alvar
WHO Collaborating Centre for Leishmaniasis, Servicio de Parasitologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain
Adv Parasitol 57:1-88. 2004....
- Leishmaniasis and povertyJorge Alvar
Communicable Diseases, Neglected Tropical Diseases Control, World Health Organization, 20 Ave Appia, CH 1211 Geneva 27, Switzerland
Trends Parasitol 22:552-7. 2006..Public investment in treatment and control would decrease the leishmaniasis disease burden and help to alleviate poverty...
- Kala-azar outbreak in Libo Kemkem, Ethiopia: epidemiologic and parasitologic assessmentJorge Alvar
Department for the Control of Neglected Tropical Diseases CDS NTD IDM, Leishmaniasis Control Program, World Health Organization, 20 Avenue Appia, CH 1211 Geneva, Switzerland
Am J Trop Med Hyg 77:275-82. 2007..Molecular typing in splenic aspirates showed L. infantum (six) and L. donovani (one). Local transmission resulted from multiple introductions, is now well established, and will be difficult to eradicate...
- Leishmaniasis worldwide and global estimates of its incidenceJorge Alvar
Department for the Control of Neglected Tropical Diseases HTM NTD IDM, Leishmaniasis Control Program, World Health Organization, Geneva, Switzerland
PLoS ONE 7:e35671. 2012..These data should help to define control strategies and reinforce leishmaniasis advocacy...
- The relationship between leishmaniasis and AIDS: the second 10 yearsJorge Alvar
Control of Neglected Tropical Diseases, World Health Organization, 20 Avenue Appia, CH 1211 Geneva 27, Switzerland
Clin Microbiol Rev 21:334-59, table of contents. 2008..Based on the previous experience of 20 years of coinfection in Europe, this review focuses on the management of Leishmania-HIV-coinfected patients in low-income countries where leishmaniasis is endemic...
- Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health OrganizationLorenzo Savioli
World Health Organization Department of Control of Neglected Tropical Diseases, Geneva, Switzerland
PLoS Med 3:e283. 2006
- Risk factors for visceral Leishmaniasis among residents and migrants in Kafta-Humera, EthiopiaDaniel Argaw
Department for the Control of Neglected Tropical Diseases CDS NTD IDM, Leishmaniasis Control Program, World Health Organization, Geneva, Switzerland
PLoS Negl Trop Dis 7:e2543. 2013..The largest focus of VL in Ethiopia is located in the lowland region bordering Sudan, where the epidemiology is complicated by the presence of thousands of seasonal agricultural workers who live under precarious conditions...
- Epidemiology of leishmaniasis in Spain based on hospitalization records (1997-2008)Ruth Gil-Prieto
Department of Preventive Medicine and Public Health and Medical Immunology and Microbiology, Rey Juan Carlos University, Madrid, Spain
Am J Trop Med Hyg 85:820-5. 2011..5 million for inpatient care alone. The economical burden of leishmaniasis is not neglectable and in the 12-year study period it represented more than $19 million...
- Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasisPiero Olliaro
UNICEF UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases WHO TDR, Geneva, Switzerland
PLoS Negl Trop Dis 7:e2130. 2013..The limited resources available for CL have to be concentrated in clinical studies of excellence that meet international quality standards...
- Chemotherapy in the treatment and control of leishmaniasisJorge Alvar
Department for Control of Neglected Tropical Diseases, World Health Organization, 20 Avenue Appia CH 1211 Geneva 27, Switzerland
Adv Parasitol 61:223-74. 2006..In addition, full deployment of drugs in treatment and control requires defined strategies, which can also prevent or delay the development of drug resistance...
- Virulence and disease in leishmaniasis: what is relevant for the patient?Luis Rivas
Centro de Investigaciones Biologicas, Consejo Superior de Investigaciones Cientificas CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain
Trends Parasitol 20:297-301. 2004
- Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot studyFernando Laguna
Servicio de Enfermedades Infecciosas, Hospital Carlos III, Instituto de Salud Carlos III, C Sinesio Delgado 12, 28029 Madrid, Spain
J Antimicrob Chemother 52:464-8. 2003..0006). The efficacy of ABLC is similar to meglumine antimoniate, but the severity of toxicity in the treatment of HIV-VL is lower with ABLC...
- Liposomal amphotericin B for the treatment of visceral leishmaniasisCaryn Bern
Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Clin Infect Dis 43:917-24. 2006..The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs...
- Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasisIsrael Cruz
WHO Collaborating Centre for Leishmaniasis, Servicio de Parasitologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Pozuelo Majadahonda Km 2, 28220 Majadahonda, Madrid, Spain
J Clin Microbiol 44:2343-7. 2006..All of the new noninvasive techniques tested showed high diagnostic sensitivity. However, LnPCR analysis of the bone marrow was the most sensitive; this test was able to detect the persistence of parasites and predict potential relapses...
- Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1Miguel A Morales
World Health Organization Collaborating Centre for Leishmaniasis, Servicio de Parasitologia, Centro Nacional de Microbiologia, Madrid, Spain
J Infect Dis 185:1533-7. 2002..These results suggest the utility of this PCR-RFLP analysis in detecting leishmaniasis reinfection in HIV-positive patients...
- Leishmania/HIV co-infections in the second decadeIsrael Cruz
WHO Collaborating Centre for Leishmaniasis, National Centre of Microbiology, Institute of Health Carlos III, Madrid, Spain
Indian J Med Res 123:357-88. 2006..An extensive review of the literature on Leishmania/HIV co-infection has allowed the inclusion of a comprehensive and updated list of bibliographical references...
- Isolation and characterization of Leishmania infantum cDNA encoding a protein homologous to eukaryotic elongation factor 1 gammaCarmen Cañavate
WHO Collaborating Centre for Leishmaniasis, Servicio de Parasitologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo km 2, 28220 Majadahonda, Madrid, Spain
Trans R Soc Trop Med Hyg 96:S41-7. 2002..Southern hybridization and pulsed field gel electrophoresis showed that EF-1 gamma genes are highly conserved among members of the Leishmania genus and must be clustered in a single chromosomal locus...
- Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasisCristina Chamizo
WHO Collaborating Centre for Leishmaniasis, Parasitology Service, National Centre of Microbiology, Instituto de Salud Carlos III, Madrid, Spain
Vet Immunol Immunopathol 103:67-75. 2005..Although both Th1 and Th2 cytokines are produced, cell mediated immunity observed in these L. infantum-infected asymptomatic dogs depended on the preferential expression of Th1 cytokines...
- Evidence for a wide occurrence of proton-translocating pyrophosphatase genes in parasitic and free-living protozoaJose R Perez-Castineira
Instituto de Bioquimica Vegetal y Fotosintesis, Universidad de Sevilla CSIC, Avda Americo Vespucio s n, Sevilla 41092, Spain
Biochem Biophys Res Commun 294:567-73. 2002..Paralogous genes were found in some species suggesting the occurrence of protein isoforms. These results indicate that H(+)-PPases are more widely distributed among protozoa than previously thought...
- Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasisEugenia Carrillo
WHO Collaborating Centre for Leishmaniasis, Centro Nacional de Microbiologia, Inst de Salud Carlos III, Majadahonda, Spain
Vaccine 26:1902-11. 2008..The identification as vaccine candidates of Leishmania antigens that elicit appropriate immune responses in the canine model is a key step in the rational approach to generate a vaccine for canine visceral leishmaniasis...
- Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?Francois Chappuis
Travel and Migration Medicine Unit, Geneva University Hospitals, 24 Rue Micheli du Crest, CH 1211 Geneva 14, Switzerland
Nat Rev Microbiol 5:873-82. 2007..New diagnostic tools and new treatment strategies will only have an impact if they are made widely available to patients...
- Canine leishmaniasis: epidemiological risk and the experimental modelJavier Moreno
WHO Collaborating Centre for Leishmaniasis, Servicio de Parasitologi a, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo km 2, 28220 Majadahonda, Spain
Trends Parasitol 18:399-405. 2002..Such studies are essential to determine the basis of the canine protective immune response and to establish a laboratory model, a significant aspect for the development of vaccines against canine leishmaniasis...
- Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patientsRogelio Lopez-Velez
Enfermedades Infecciosas, Hospital Ramon y Cajal, Carretera de Colmenar, Km 9 100, 28034 Madrid, Spain
J Antimicrob Chemother 53:540-3. 2004..The aim of this study was to evaluate the efficacy and safety of amphotericin B lipid complex (ABLC) in preventing VL relapses in HIV-infected patients...